RESEARCH ARTICLE

Vitreous levels of Lipocalin-2 on patients with primary rhegmatogenous retinal detachment

Georgios Batsos1*, Eleni Christodoulou1, Georgios Vartholomatos2, Petros Galanis3, Maria Stefaniotou1

1 Ophthalmology Department, University Hospital Of Ioannina, Ioannina, Greece, 2 Haematology Laboratory Unit of Molecular Biology, University Hospital Of Ioannina, Ioannina, Greece, 3 Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens (NKUA), Athens, Greece

* batsosgeorge@gmail.com

Abstract

Purpose

To measure vitreous levels of Lipocalin2 (LCN2) in patients with rhegmatogenous retinal detachment (RRD) and investigate potential association with presence of proliferative vitreoretinopathy (PVR).

Materials and methods

Collection of undiluted vitreous samples from 24 patients suffering from RRD and 10 control patients undergoing vitrectomy for: vitreomacular traction (VMT) (n = 2), idiopathic epiretinal membrane (iERM) (n = 6) and full thickness macular hole (FTMH) (n = 2). Quantitative analysis of LCN2 has been made with flow cytometry. Lens status, duration of symptoms, quadrants of detachment, as well as level of PVR, were assessed. Statistical analysis included Mann-Whitney test, Kruskal-Wallis test, t-test, Spearman’s correlation coefficient and Fisher’s exact test.

Results

Median LCN2 was significantly higher in the RRD group as compared to control (p<0.001). Within the RRD group there was a positive correlation between LCN2 and PVR grade ($r_s = 0.94$, p<0.001). Median LCN2 was 35,759 pg/ml (IR = 55,347) in grade C PVR, 9,387 pg/ml (IR = 3721) in grade B, 4,917 pg/ml (IR = non computable) in grade A and 3,921 pg/ml (2132) in the no PVR group. Median LCN2 was also significantly higher in pseudophakic patients as compared to phakic patients (p = 0.007). LCN2 also correlates with the extend of detachment ($\leq 2$ vs $>2$ quadrants, p<0.001) as well as with duration of symptoms ($r_s = 0.87$, p<0.001). After multivariate linear regression analysis, only PVR was independently related with LCN2 concentration. In particular, increased PVR grading was associated with increased LCN2 concentration (coefficient b = 2.97, 95% confidence interval = 1.89 to 4.67, p<0.001).
Conclusion
A positive correlation between vitreous levels of LCN2 and PVR grading reveals a potential role in the pathogenesis and progression of PVR. Further studies could elucidate if LCN2 could be a therapeutic target.

Introduction
Nowadays, single operation success rate in the management of retinal detachment is approximately 80% [1–4]. However, nearly 10% of patients will need repeat surgery due to the risk of recurrence [5] mostly from Proliferative Vitreoretinopathy (PVR), which remains an unsolved problem for patients and vitreoretinal surgeons.

PVR is characterized by cell migration and proliferation in the peri-retinal space accompanied by the development of pre-retinal and sub-retinal membranes. As a result of the aforementioned as well as additional alterations [6, 7], retina traction with subsequent contraction ensue. It occurs in 5–10% of rhegmatogenous retina detachment (RRD) cases, and in 75% of re-detachments after a successful surgical repair [8].

Many factors and mediators are implicated in PVR pathogenesis [7, 9–14]. Various studies and clinical trials for the pharmaceutical treatment or prevention of PVR have been performed [15]; yet the standard treatment remains surgical [16].

Latest research is focused on determining biomarkers related to PVR [7, 17–19]. One of the major contributors in PVR development is inflammation [8, 12, 20, 21]. The inflammatory process which is initiated after a rhegmatogenous retinal detachment, is driven by various cytokines and growth factors [15]. Moreover the degree of inflammation is related to the remodeling mechanisms leading to PVR formation [7]. Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is an adipokine involved in a variety of processes such as metabolic homeostasis, apoptosis, infection, immune response, or inflammation. Elevated levels of lipocalin2 have also been measured in the aqueous humor of patients with idiopathic acute anterior uveitis (AAU) [22] as well as in patients with branch retinal vein occlusion (BRVO) [23]. LCN2 levels have been proposed as a biomarker for various inflammatory diseases [24, 25], [26], [27], [28] [29], [30] [31–33] but its role in RRD and PVR has not been examined thus far and is the aim of this study.

Materials and methods
This study was conducted at the University Hospital of Ioannina, Greece, between March and July 2019, after receiving approval from the hospital’s ethics committee “Scientific Board” (March 2019). During that period, patients recruited from the hospital’s Ophthalmology clinic (Vitreoretinal Department). Written informed consent was obtained before each surgery. The study is adherent to the tenets of the Declaration of Helsinki.

Vitreous samples were collected from 24 RRD patients (17 males, 7 females) aged between 35 and 86 years. Our control group comprised of 10 patients (3 males and 7 females), undergoing vitrectomy for various vitreoretinal pathologies other than RRD; 6 were diagnosed with idiopathic epiretinal membrane (iERM), 2 with vitreomacular traction syndrome (VMT), and 2 with full-thickness macular hole (FTMH). Age in the control group ranged from 51 to 84 years. Complete ophthalmic examination was performed to all patients. In the RRD group, we also assessed lens status (2 groups: phakic, pseudophakic), quadrants of involvement (2 groups:
1–2, 3–4), symptom duration (3 groups <10, 10–30, >30 days), and PVR grading (if present) according to the Retina Society Classification (1991) [34–36].

Patients with a history of ocular trauma, prior ophthalmic surgery other than phacoemulsification, history of diabetes mellitus, or an undergoing systemic inflammatory disease were excluded from this study.

All patients were operated by the same surgeon with standard 25G pars plana vitrectomy. Approximately 0.5ml of undiluted vitreous core sample was collected at the beginning of vitrectomy, just before the opening of the infusion cannula. Samples were stored at -80 °C.

Flow cytometry
Results were analyzed via the CellQuest software (Becton-Dickinson). Sample analysis was performed using AimPlex multiplex assay on a FACSCalibur (Becton-Dickinson) flow cytometer via a three-step process. A 60-minute incubation with an antibody-conjugated bead was followed by a 30-minute biotinylated detection step; the latter preceded a final 20-minute Streptavidin-Phycoerythrine (PE) incubation. LCN2 (NGAL) concentrations were obtained by comparing the fluorescent signals to those of a standard curve (Fig 1). Results were calculated from such standard curves and expressed as picograms per milliliter (pg/mL).

Fig 2 illustrates vitreous expression of LCN2 (NGAL) in a RRD (a) and a (FTMH) (b), respectively.

Statistical analysis
Quantitative variables did not follow the normal distribution and were summarized as median (interquartile range), whereas categorical data were expressed as percentages (frequencies) of the groups. Non-normally distributed data were compared using nonparametric methods to assess statistical significance. For quantitative variables, differences between two groups were evaluated with Mann–Whitney U test. Kruskal–Wallis test was applied in cases of more than two groups of quantitative variables. Correlation between two quantitative variables was quantified using Spearman’s correlation coefficient. Variability between the RRD and the control group in terms of age and gender was assessed with independent-samples t-test and chi-square test. To eliminate confounding, we then performed multivariate linear regression analysis.
using LCN2 levels in the RRD group as the dependent variable. Since the latter did not follow a normal distribution pattern, we used its logarithm for further analysis. This was followed by a backward stepwise elimination method which enabled us to calculate coefficient beta, 95% confidence interval and p-values. Sensitivity analysis was performed in case of presence of outliers. A two tailed p-value of less than 0.05 was considered statistically significant. Statistical analysis was performed with the Statistical Package for Social Sciences software (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.).

**Results**

**Demographics**

There were no differences in age and gender between RRD group and controls. In particular, mean age in the RRD group was 64.1 years (standard deviation [SD] = 13.2) while in the control group was 69.9 years (SD = 9.1) (t = -1.2, p = 0.2). In RRD patients 85% (n = 17) were males, while in controls it was 50% (n = 7) were males ($\chi^2 = 4.9, p = 0.054$).

LCN2 levels of the patients and the controls are shown in Table 1. The median concentration of LCN2 was markedly higher in patients with RRD than in controls (U = 27, p < 0.001). In particular, median LCN2 concentration in the RRD group was 7,095 pg/ml (IR = 9,605), while in controls was 3,289 pg/ml (IR = 3,090) (Fig 3).

We found a positive correlation between LCN2 concentration and PVR grading ($r_s = 0.94, p < 0.001$). Median concentration of LCN2 in PVR C group was 35,759 pg/ml (IR = 55,347), in PVR B group was 9,387 pg/ml (IR = 3,721), in PVR A group was 4,916 pg/ml (IR = non computable) and in no PVR group was 3,921 pg/ml (IR = 2,132).

Regarding the lens status in the RRD group, the median LCN2 concentration was significantly higher in pseudophakic compared to phakic patients (U = 25, p = 0.007). In particular, median LCN2 concentration in pseudophakic patients was 13,124 pg/ml (IR = 40,014), while in phakic patients was 4,879 pg/ml (IR = 4550).

The extent of retinal detachment seems to be correlated with the levels of LCN2 (U = 3, p < 0.001). In particular, median LCN2 concentration in patients with 3–4 quadrants of involvement was 10,005 pg/ml (IR = 21,316), while in patients with 1–2 quadrants of involvement was 3,921 pg/ml (IR = 2132).
Table 1. LCN2 levels of patients and controls.

|                        | LCN2 levels |                  |                  |                  | Interquartile range | N  | P-value       | P-value after sensitivity analysis |
|------------------------|-------------|------------------|------------------|------------------|---------------------|----|---------------|------------------------------------|
|                        |             | Mean             | Standard deviation | Median           | Minimum value | Maximum Value |                     |                                     |
| Controls               |             | 2.975            | 1.634             | 3.289            | 200           | 4,803         | 3,090          | <0.001<sup>a</sup>               | 0.001<sup>a</sup>                |
| RRD (total)            |             | 23.481           | 52,926            | 7,095            | 2,311         | 259,625       | 9,605          |                                     |                                      |
| Lens status            |             |                  |                   | 0.007<sup>a</sup> | 0.082<sup>a</sup>|                  |                       |                                     |                                      |
| Phakic                 |             | 5.824            | 2,720             | 4,879            | 2,311         | 10,527        | 4,550          | 0.001<sup>a</sup>               | 0.001<sup>a</sup>                |
| Pseudophakic           |             | 41.137           | 71,899            | 13,124           | 2,520         | 259,625       | 40,014         | 12                                  |                                      |
| PVR grading            |             |                  |                   |                 |               |               |                  |                                     |                                      |
| No PVR                 |             | 3.779            | 1,209             | 3,921            | 2,311         | 5,561         | 2,132          | <0.001<sup>b</sup>               | <0.001<sup>b</sup>               |
| PVR A                  |             | 5.084            | 358               | 4,916            | 4,541         | 5,495         | Non computable | 3                                  |                                      |
| PVR B                  |             | 8.609            | 1,879             | 9,387            | 6,055         | 10,763        | 3,721          | 7                                  |                                      |
| PVR C                  |             | 65.938           | 88,032            | 35,759           | 10,527        | 259,625       | 55,346         | 7                                  |                                      |
| Quadrants              |             |                  |                   |                 |               |               |                  |                                     |                                      |
| 1–2                    |             | 3.779            | 1,209             | 3,921            | 2,311         | 5,561         | 2,132          | <0.001<sup>a</sup>               | <0.001<sup>a</sup>               |
| 3–4                    |             | 31.593           | 61,534            | 10,005           | 4841          | 259,625       | 21,316         | 17                                 |                                      |
| Symptoms duration      |             |                  |                   |                 |               |               |                  |                                     |                                      |
| (days)                 |             |                  |                   |                 |               |               |                  |                                     |                                      |
| <10                    |             | 4.023            | 1,155             | 4,479            | 2,311         | 5,561         | 2,113          | 9                                  |                                      |
| 11–30                  |             | 15.580           | 19,802            | 9625             | 5495          | 70,883        | 6,649          | 10                                 |                                      |
| >30                    |             | 74.304           | 104,81            | 35,759           | 10,527        | 259,625       | 141,867        | 5                                  |                                      |

<sup>a</sup> Mann-Whitney  
<sup>b</sup> Spearman’s correlation coefficient

https://doi.org/10.1371/journal.pone.0227266.t001

Fig 3. LCN2 (NGAL) levels of the patients and the controls (U = 27, p < 0.001). Circles denote mild outliers and asterisks denote extreme outliers.

https://doi.org/10.1371/journal.pone.0227266.g003
There was also a positive correlation between symptom duration and LCN2 concentration in the RRD group ($r_s = 0.87$, $p < 0.001$). In RRD patients, symptomatic for more than 30 days, median LCN2 was 35,759 pg/ml (IR = 141,867). In patients with symptom duration of 10 to 30 days the median LCN2 concentration was 9,625 pg/ml (IR = 6,649). In RRD patients having symptoms less than 10 days, the median concentration of LCN2 was 4,479 pg/ml ($x^2 = 17.7$, $p < 0.001$).

After multivariate linear regression analysis, only PVR was independently correlated with LCN2 concentration. In particular, increased PVR grading was associated with increased LCN2 concentration (coefficient $b = 2.97$, 95% confidence interval = 1.89 to 4.67, $p < 0.001$, $R^2 = 66$%). Results did not change after sensitivity analysis (coefficient $b = 1.57$, 95% confidence interval = 1.41 to 1.76, $p < 0.001$, $R^2 = 79$%).

Discussion

In this study, we found elevated LCN2 levels in the vitreous of RRD patients. To our knowledge, this has not been reported to the literature so far. Lipocalin-2 is regarded as a biomarker for several inflammatory diseases [32]. Recent studies have revealed its regulatory role in ocular inflammation and retinal degeneration observed in the setting of diseases such as Stargardt, retinitis pigmentosa and age related macular degeneration [37]. Tanu Parmar et al., also described that LCN2 contributes to acute stress response and immune activation of Retinal Pigmented Epithelium (PRE) cells in Abca4$^{-/-}$Rdh8$^{-/-}$ mice after light exposure [38]. Moreover, Mallika Vapalla et al. correlated the increase in RPE Lipocalin-2 levels with chronic inflammatory conditions, in Cryba1 cKO mice simulating age-related macular degeneration (AMD) [39].

LCN2 is also known to modulate matrix metalloproteinase-9 (MMP-9) activity [40–43]; a mediator involved in normal, as well as in the pathologic wound healing characterizing PVR [44–46]. LCN2 seems to play a role in reactive gliosis and neuroinflammation [47, 48], components which are also implicated in PVR pathophysiology [7, 49, 50].

Limitations of this study include the number of recruited patients and the unknown time interval between phacoemulsification and retinal detachment when comparing phakic and pseudophakic patients with RRD.

In summary, we found elevated vitreous levels of LCN2 in patients with RRD and an association between LCN2 expression and PVR grade. Moreover, the vitreous LCN2 overexpression seems to be correlated with some other relevant clinical parameters such as the lens status, the extent of the detachment as well as the symptom duration. Our findings highlight the potential role of lipocalin2 in the development and progression of PVR, supplementing previous studies trying to elucidate its role in inflammation and reactive gliosis. Larger prospective studies are highly encouraged in order to determine the precise role of lipocalin2 as a potential PVR biomarker or therapeutic target.

Supporting information

S1 Datasheet. Summary table of the data collected from each patient record.

(DOCX)

Author Contributions

Conceptualization: Georgios Batsos.

Data curation: Eleni Christodoulou.
Formal analysis: Georgios Vartholomatos, Petros Galanis.

Investigation: Georgios Batsos.

Methodology: Georgios Batsos.

Project administration: Maria Stefaniotou.

Resources: Eleni Christodoulou.

Supervision: Maria Stefaniotou.

Writing – original draft: Georgios Batsos.

Writing – review & editing: Georgios Batsos, Maria Stefaniotou.

References

1. Mohamed YH, Ono K, Kinoshita H, et al. Success Rates of Vitrectomy in Treatment of Rhegmatogenous Retinal Detachment. Journal of ophthalmology. 2016; 2016:2193518.

2. The Royal College of Ophthalmologists. National Electronic Retinal Detachment Surgery Audit: Feasibility Report. 2017 [cited 2019 10 Aug]; https://www.nodaudit.org.uk/docs/20/komnfeval2/RetinalDetachmentSurgeryAuditFeasibilityReport.pdf.

3. 2018 MEAEDoO. Quality and Outcomes. 2018 [cited 2019 10 Aug]; https://www.masseyeandear.org/assets/MEE/pdfs/about/ophtalmology-quality-2018.pdf.

4. Schaal S, Sherman MP, Barr CC, et al. Primary retinal detachment repair: comparison of 1-year outcomes of four surgical techniques. Retina (Philadelphia, Pa). 2011; 31(8):1500–4.

5. Enders P, Schick T, Schaub F, et al. Risk of Multiple Recurring Retinal Detachment after Primary Rhegmatogenous Retinal Detachment Repair. Retina (Philadelphia, Pa). 2017; 37(5):930–5.

6. Charteris DG, Downie J, Aylward GW, et al. Intradiscal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2007; 245(1):93–100. https://doi.org/10.1007/s00417-006-0323-5 PMID: 16612635

7. Pastor JC, Rojas J, Pastor-Idoate S, et al. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Progress in retinal and eye research. 2016; 51:125–55. https://doi.org/10.1016/j.preteyeres.2015.07.005 PMID: 26209346

8. Sadaka A, Giulari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol. 2012; 6:1325–33. https://doi.org/10.2147/OPTH.S27896 PMID: 22942638

9. Pennock S, Haddock LJ, Elliott D, et al. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Progress in retinal and eye research. 2014; 40:16–34. https://doi.org/10.1016/j.preteyeres.2013.12.006 PMID: 24412519

10. Rouberol F, Chiquet C. [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis]. Journal francais d’ophtalmologie. 2014; 37(7):557–65. https://doi.org/10.1016/j.jfo.2014.04.001 PMID: 24997864

11. Pastor JC. Proliferative vitreoretinopathy: an overview. Survey of ophthalmology. 1998; 43(1):3–18. https://doi.org/10.1016/s0039-6257(88)00023-8 PMID: 9716190

12. Pastor JC, de la Rua ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Progress in retinal and eye research. 2002; 21(1):127–44. https://doi.org/10.1016/s1350-9462(01)00023-4 PMID: 11906814

13. Leaver PK. Proliferative vitreoretinopathy. The British journal of ophthalmology. 1995; 79(10):871–2. https://doi.org/10.1136/bjo.79.10.871 PMID: 7488570

14. Laqua H, Machemer R. Glial cell proliferation in retinal detachment (massive periretinal proliferation). American journal of ophthalmology. 1975; 80(4):602–18. https://doi.org/10.1016/0002-9394(75)90390-6 PMID: 810029

15. Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators of inflammation. 2012; 2012:815937.

16. Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina (Philadelphia, Pa). 2015; 35(2):165–75.
17. Ricker LJ, Kessels AG, de Jager W, et al. Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling. American journal of ophthalmology. 2012; 154(2):347–54 e2. https://doi.org/10.1016/j.ajo.2012.02.004 PMID: 22541653

18. Wang F, Yu J, Qiu QH, et al. [Kininogen-1 and insulin-like growth factor binding protein-6 as serum biomarkers for proliferative vitreoretinopathy]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology. 2010; 46(7):609–14. PMID: 21054688

19. Zandi S, Pfister IB, Traine PG, et al. Biomarkers for PVR in rhegmatogenous retinal detachment. PLoS one. 2019; 14(4):e0214674. https://doi.org/10.1371/journal.pone.0214674 PMID: 30943234

20. Tosi GM, Marigliani D, Romeo N, et al. Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. Journal of cellular physiology. 2014; 229(11):1577–83. https://doi.org/10.1002/jcp.24606 PMID: 24604697

21. Charteris DG, Sethi CS, Lewis GP, et al. Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology. Eye (London, England). 2002; 16(4):369–74.

22. Salom D, Sanz-Marco E, Mullor JL, et al. Aqueous humor neutrophil gelatinase-associated lipocalin levels in patients with idiopathic acute anterior uveitis. Molecular vision. 2010; 16:1448–52. PMID: 20680102

23. Koban Y, Sahin S, Boy F, et al. Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. International ophthalmology. 2018.

24. Wilson R, Belluccio D, Little CB, et al. Proteomic characterization of mouse cartilage degradation in vitro. Arthritis and rheumatism. 2008; 58(10):3120–31. https://doi.org/10.1002/art.23789 PMID: 18821673

25. Chakraborty S, Kaur S, Guha S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochimica et biophysica acta. 2012; 1826(1):129–69. https://doi.org/10.1016/j.bbagrm.2011.10.007 PMID: 22513004

26. Lindberg S, Jensen JS, Mogelvang R, et al. Plasma neutrophil gelatinase-associated lipocalin in the general population: association with inflammation and prognosis. Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(9):2135–42. https://doi.org/10.1161/ATVBAHA.113.303950 PMID: 24969771

27. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2008; 52(3):595–605.

28. Brunner HI, Bennett MR, Mina R, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis and rheumatism. 2012; 64(8):2687–97. https://doi.org/10.1002/art.34426 PMID: 22328173

29. Chassaing B, Srinivasan G, Delgado MA, et al. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PloS one. 2012; 7(9):e44328. https://doi.org/10.1371/journal.pone.0044328 PMID: 22957064

30. Berard JL, Zarruk JG, Arbour N, et al. Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia. 2012; 60(7):1145–59. https://doi.org/10.1002/glia.22342 PMID: 22499213

31. Jang Y, Lee JH, Wang Y, et al. Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome. Clinical and experimental pharmacology & physiology. 2012; 39(2):194–9.

32. Abella V, Scotece M, Conde J, et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2015; 20(8):565–71.

33. Zhang J, Wu Y, Zhang Y, et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008; 22(6):1416–26. https://doi.org/10.1210/me.2007-0420 PMID: 18292240

34. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. American journal of ophthalmology. 1991; 112(2):159–65. https://doi.org/10.1016/s0002-9394(14)76695-4 PMID: 1867299

35. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983; 90(2):121–5. https://doi.org/10.1016/s0161-6420(83)34588-7 PMID: 6856248

36. Lean JS, Stern WH, Irvine AR, et al. Classification of proliferative vitreoretinopathy used in the silicone study. The Silicone Study Group. Ophthalmology. 1989; 96(6):765–71. https://doi.org/10.1016/s0161-6420(89)32821-1 PMID: 2662099

37. Parmar T, Parmar VM, Perusek L, et al. Lipocalin 2 Plays an Important Role in Regulating Inflammation in Retinal Degeneration. J Immunol. 2018; 200(9):3128–41. https://doi.org/10.4049/jimmunol.1701573 PMID: 29602770
38. Parmar T, Parmar VM, Arai E, et al. Acute Stress Responses Are Early Molecular Events of Retinal Degeneration in Abca4−/-Rdh8−/- Mice After Light Exposure. Investigative ophthalmology & visual science. 2016; 57(7):3257–67.

39. Valapala M, Edwards M, Hose S, et al. Increased Lipocalin-2 in the retinal pigment epithelium of Cryba1 cKO mice is associated with a chronic inflammatory response. Aging cell. 2014; 13(6):1091–4. https://doi.org/10.1111/acel.12274 PMID: 25257511

40. Hofmaier F, Hauck SM, Amann B, et al. Changes in matrix metalloproteinase network in a spontaneous autoimmune uveitis model. Investigative ophthalmology & visual science. 2011; 52(5):2314–20.

41. Kubben FJ, Sier CF, Hawinkels LJ, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodigestion and the impact for gastric cancer. Eur J Cancer. 2007; 43(12):1869–76. https://doi.org/10.1016/j.ejca.2007.05.013 PMID: 17604154

42. Yan L, Borregaard N, Kjeldsen L, et al. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. The Journal of biological chemistry. 2001; 276(40):37258–65. https://doi.org/10.1074/jbc.M106089200 PMID: 11486009

43. Kobayashi T, Kim H, Liu X, et al. Matrix metalloproteinase-9 activates TGF-beta and stimulates fibroblast contraction of collagen gels. American journal of physiology Lung cellular and molecular physiology. 2014; 306(11):L1006–15. https://doi.org/10.1152/ajplung.00015.2014 PMID: 24705725

44. Symeonidis C, Papakonstantinou E, Souliou E, et al. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta ophthalmologica. 2011; 89(4):339–45. https://doi.org/10.1111/j.1755-3768.2009.01701.x PMID: 19764916

45. Kon CH, Occleston NL, Charteris D, et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Investigative ophthalmology & visual science. 1998; 39(8):1524–9.

46. Zeng J, Jiang D, Zhu X, et al. [A quantitative study of matrix metalloproteinases in proliferative vitreoretinopathy]. Yan ke xue bao = Eye science. 2003; 19(2):130–2. PMID: 12870353

47. Tassoni A, Gutteridge A, Barber AC, et al. Molecular Mechanisms Mediating Retinal Reactive Gliosis Following Bone Marrow Mesenchymal Stem Cell Transplantation. Stem cells (Dayton, Ohio). 2015; 33(10):3006–16.

48. Lee S, Park JY, Lee WH, et al. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(1):234–49.

49. Eastlake K, Heywood WE, Banerjee P, et al. Comparative proteomic analysis of normal and gliotic PVR retina and contribution of Muller glia to this profile. Experimental eye research. 2018; 177:197–207. https://doi.org/10.1016/j.exer.2018.08.016 PMID: 30176221

50. Eastlake K, Banerjee PJ, Angbohang A, et al. Muller glia as an important source of cytokines and inflammatory factors present in the gliotic retina during proliferative vitreoretinopathy. Glia. 2016; 64(4):495–506. https://doi.org/10.1002/glia.22942 PMID: 26556395